Clinical trials: STEMI - ST-segment Elevation Myocardial Infarction
ST-elevation Myocardial Infarction (STEMI)
Use of BVS in ST-segment Elevation Myocardial Infarction (STEMI): the BVS STEMI STRATEGY-IT Prospective Registry
BVS STEMI STRATEGY-IT is a spontaneous, prospective, non-randomized, single-arm multicenter registry on consecutive STEMI patients eligible to undergo primary percutaneous coronary intervention (PPCI) with BVS implantation on the…
- Trial name
- STRATEGY-IT (NCT02601781)
- Testing
- Primary percutaneous coronary intervention (PPCI), Bioresorbable Vascular Scaffold (BVS ABSORB)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Azienda Ospedaliera Bolognini di Seriate Bergamo
No-Reflow Phenomenon
Intracoronary Tirofiban on No-Reflow Phenomena
The goal of this study was to evaluate the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with STEMI and occurrence of no-reflow phenomenon undergoing primary percutaneous coronary…
- Trial name
- NCT02054000
- Testing
- Tirofiban
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people
- Sponsor
- TC Erciyes University
Unstable Angina or Non ST Elevated Myocardial Infarction
Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers
To evaluate the impact on outcomes of the currently accepted antithrombotic strategies based on the administration of newer P2Y12 receptor blockers (prasugrel and ticagrelor) in a population of non ST elevated ACS (NSTEACS)…
- Trial name
- DUBIUS (NCT02618837)
- Testing
- Downstream strategy, Upstream strategy
- Where
- Italy
- Volunteers
- 2,520 people
- Sponsor
- University of Padova
Coronary Disease, Myocardial Infarction
A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration.
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Diseases, Vascular Diseases
- Trial name
- CEL-02 (NCT04284995)
- Testing
- RUC-4 Compound
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- CeleCor Therapeutics
Acute ST Segment Elevation Myocardial Infarction
Platelet Function in Resuscitated Patients
Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab.
- Trial name
- NCT02914795
- Testing
- diagnostic analysis of platelet function
- Where
- Austria
- Volunteers
- 99 people
- Sponsor
- Medical University of Graz
Myocardial Infarction
Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction
To investigate the effect and safety of intracoronary autologous bone morrow mesenchymal stem cells (BM-MSCs) transplantation in patients with ST-segment elevation myocardial infarction（ STEMI） .
- Trial name
- Bmmsct (NCT04421274)
- Testing
- Bone marrow mesenchymal stem cells transfer, Best medical treatment, Percutaneous coronary intervention
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
STEMI, STEMI (ST Elevation MI)
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage.
- Conditions
- STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation
- Trial name
- NCT06678074
- Testing
- Atibuclimab (IC14), 20 mg/kg intravenously, once
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Implicit Bioscience
Cardiovascular Diseases
ST-Segment Resolution as a Marker for Myocardial Scar in ST-Segment Elevation Myocardial Infarction
Clinical studies found that poor ST-segment resolution (STR) in electrocardiogram (ECG) occurred in major adverse cardiovascular events (MACE), arrhythmia and heart failure was significantly higher .
- Trial name
- NCT04586582
- Testing
- ST-segment resolution <40.15%
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chongqing Medical University
Coronary Artery Disease, Aortic Valve Disease
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
The goal of the 3D-CARDIOPATH study is to investigate the potential added value of emerging 3D imaging modalities by imaging ex vivo cardiac specimens (diseased coronary arteries, calcific aortic valves, and thrombotic materials)…
- Conditions
- Coronary Artery Disease, Aortic Valve Disease, Aortic Valve Calcification, STEMI
- Trial name
- 3D-CARDIOPATH (NCT05975567)
- Testing
- Three-dimensional imaging of the collected cardiac specimens
- Volunteers
- 70 people
- Sponsor
- Aristotle University Of Thessaloniki
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Diabetes, STEMI
Sweetheart-Register: Risk Management of Diabetics with Acute Myocardial Infarction
The Sweetheart register (Risk management of Diabetics with acute myocardial infarction) documents both the prevalence of pathologic glucose metabolism in consecutive high-risk patients with STEMI and NSTEMI in daily hospital…
- Conditions
- Diabetes, STEMI, NSTEMI, Myocardial Infarction
- Trial name
- Sweetheart (NCT01197742)
- Where
- 2 sites in Germany
- Volunteers
- 2,772 people
- Sponsor
- Stiftung Institut fuer Herzinfarktforschung
STEMI - ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease
In-hospital Versus After-discharge Complete Revascularization
Patients with STEMI and multivessel disease in whom the culprit lesion has been successfully revascularized during prmimary PCI, will be randomized to in-hospital or after-discharge complete revascularization.
- Trial name
- REVIVA-ST (NCT04743154)
- Testing
- In-hospital nonculprit-lesions percutaneous coronary intervention (PCI), After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital General Universitario de Valencia
ST Elevation Myocardial Infarction, Cardiogenic Shock
Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City
A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during…
- Trial name
- NCT06535503
- Where
- 2 sites in United Arab Emirates
- Volunteers
- 400 people
- Sponsor
- Abu Dhabi Health Services Company
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
STEMI, Oxidative Stress
Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI
The investigators intend to evaluate Oxidative Stress biomarkers through a. Catalase Activity Assay; b. Lipid Peroxidation Assay; c. SOD Assay; d. Total Antioxidant Capacity Assay; e.
- Conditions
- STEMI, Oxidative Stress, Oxidative Stress Induction, Primary PCI
- Trial name
- OxiSTEMIhFABP (NCT04034940)
- Testing
- Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
STEMI, Cardiogenic Shock
Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock
The aim of the study is knowing the prognostic value of circulating miRNAs in patients admitted to our hospital with STEMI complicated with cardiogenic shock.
- Conditions
- STEMI, Cardiogenic Shock, Acute Coronary Syndrome, microRNA
- Trial name
- NCT02691286
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ST-segment Elevation Myocardial Infarction (STEMI)
Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
To investigate the predictive value of PRECISE DAPT score in relation to coronary slow flow \& other short term major adverse cardiovascular events (MACE) post PPCI .
- Trial name
- NCT04549766
- Testing
- calculate PRECISE DAPT score using clinical data
- Volunteers
- 150 people
- Sponsor
- Assiut University
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT01770613
- Testing
- Stem cells
- Where
- 2 sites in United States
- Sponsor
- Stemedica Cell Technologies, Inc.
Non-ST-segment Elevation Myocardial Infarction
Study on High-sensitivity Troponin 0h/1h for Rapid Diagnosis of Non-ST-segment Elevation Myocardial Infarction in the Chinese Population
The purpose of the study is to establish a high-sensitivity troponin 0h/1h process for the diagnosis of patients suspected of NSTEMI for the Chinese population, obtain the inclusion and exclusion criteria for diagnosis of these…
- Trial name
- NCT03331549
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Anzhen Hospital
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.